VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Wednesday, detailing progress during the first half of 2026. The company reported continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. VERAXA's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs, and two non-BiTAC assets available for partnering.
The company plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development. Specifically, VERAXA aims to advance its lead BiTAC-TCE candidate, VXA-102, to IND/CTA readiness by early 2028. This pipeline strategy reflects a focused approach to allocate resources toward the most promising assets while leveraging non-core programs to generate capital.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
The BiTAC platform is designed to overcome limitations of conventional bispecific antibodies by enabling more potent and durable T-cell activation against solid tumors. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company's pipeline reflects a combination of in-house innovation and strategic partnerships to accelerate development.
For investors, the update underscores VERAXA's commitment to advancing its core BiTAC technology while exploring partnership opportunities to extend its financial runway. The company's ability to secure collaborations will be critical as it moves VXA-102 toward the clinic. More details are available in the full press release at https://ibn.fm/xTF5q.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. For the latest news and updates relating to VRXA, visit the company’s newsroom at http://ibn.fm/VRXA.
